L-Glutamine for Leaky Gut: Dosing & Evidence (2026)

L-glutamine is the most abundant amino acid in the human body and the primary fuel source for enterocytes, the cells lining the intestinal wall. One double-blind RCT (Zhou et al., 2019) found that 15 g/day reduced IBS-D symptoms in 79.6% of participants versus 5.8% on placebo. A 2024 meta-analysis of 10 studies then complicated the picture: only doses above 30 g/day produced statistically significant improvements in intestinal permeability. The standard recommendation of 5 to 10 g/day, repeated across nearly every supplement guide online, sits well below either of these thresholds. Evidence grade: B (strong RCT plus supportive meta-analysis subgroup data).

What L-Glutamine Does in the Gut

Enterocytes are among the most metabolically active cells in the body. They turn over every 3 to 5 days. Their preferred fuel is not glucose. Glutamine supplies 60 to 70% of the energy that small intestinal epithelial cells consume, making it the single most important nutrient for maintaining the intestinal barrier.

The intestinal barrier covers roughly 400 square meters of surface area. A single cell layer thick. The barrier itself depends on tight junction proteins: claudins, occludin, and zonula occludens-1 (ZO-1). These proteins form the seals between adjacent enterocytes, controlling what passes from the intestinal lumen into the bloodstream. When glutamine is depleted, tight junction expression falls. Permeability rises. Bacterial endotoxins, undigested food proteins, and other antigens cross into systemic circulation.

The enzyme glutaminase converts glutamine into glutamate and ammonia within enterocytes. This reaction drives the citric acid cycle, generating the ATP that powers active transport, mucus secretion, and the constant cell division required to replace the epithelial lining every few days. Colonocytes (large intestine cells) rely more on short-chain fatty acids like butyrate, but small intestinal enterocytes depend on glutamine as their primary energy currency. During periods of fasting, illness, or high physical stress, the small intestine competes with immune cells and skeletal muscle for a shrinking pool of circulating glutamine.

This is the mechanism that Alessio Fasano's research at Harvard has mapped in detail. Fasano identified zonulin as the primary physiological modulator of intestinal permeability. When zonulin levels rise (triggered by gliadin exposure, bacterial overgrowth, or other insults), tight junctions open. The resulting permeability increase allows antigen translocation that can trigger autoimmune cascades in genetically susceptible individuals. Glutamine works upstream of this process by supporting the structural integrity of tight junctions and providing the metabolic fuel enterocytes need to maintain barrier function.

A 2015 review in Physiological Reviews (PMC 4369670) detailed the specific tight junction changes that occur during glutamine depletion. Claudin-1 and claudin-4 expression drops, widening the paracellular space. ZO-1 redistributes from its normal position at the tight junction to the cytoplasm, breaking the scaffold that holds the barrier together. Glutamine supplementation reverses these changes in cell culture and animal models, restoring the protein architecture within hours of repletion.

Beyond structural support, glutamine influences intestinal immune function directly. It serves as a nitrogen donor for nucleotide synthesis in rapidly dividing immune cells within the gut-associated lymphoid tissue (GALT). Seventy percent of the body's immune cells reside in or near the gut. These cells require glutamine for proliferation, cytokine production, and phagocytic activity. During physiological stress, infection, or intense exercise, plasma glutamine levels drop by 20 to 40%, creating a functional deficit that compromises both barrier integrity and local immune surveillance.

Athletes provide a useful illustration. A 2017 dose-response study (PMC 5694515) found that glutamine supplementation protected against exercise-induced intestinal permeability in a dose-dependent manner. Higher doses produced greater barrier protection, consistent with the dose-response relationship that would later emerge in the 2024 meta-analysis.

The Clinical Evidence

Zhou 2019: The Strongest Single Study

Zhou et al. (2019, Gut) conducted a double-blind, placebo-controlled RCT in 106 patients with post-infectious IBS-D (diarrhea-predominant irritable bowel syndrome following an acute enteric infection). Participants received either 5 g of L-glutamine three times daily (15 g total) or placebo for 8 weeks.

The results were striking. In the glutamine group, 79.6% met the primary endpoint of a greater than 50-point reduction in IBS-SSS (IBS Severity Scoring System). In the placebo group, 5.8% met the same threshold. That is a 14-fold difference.

The study also measured intestinal permeability using the lactulose-to-mannitol (L:M) ratio, a validated biomarker for barrier integrity. Glutamine normalized the L:M ratio, confirming that the clinical improvement corresponded to measurable restoration of gut barrier function. Stool frequency decreased. Daily bowel movements normalized. The effect was durable through the 8-week study period.

One important caveat: the study population had post-infectious IBS specifically, meaning they had documented increased intestinal permeability at baseline. Patients with intact barrier function would not be expected to show the same magnitude of benefit. The study enrolled participants with confirmed elevated L:M ratios, selecting for those most likely to respond.

2024 Meta-Analysis: What Most Guides Miss

A meta-analysis published in Amino Acids (October 2024) pooled data from 10 studies with 352 total participants examining glutamine's effect on intestinal permeability across various populations and protocols.

The overall pooled result was not statistically significant. Glutamine, when analyzed across all doses and durations, did not produce a reliable reduction in intestinal permeability. This is the finding that most supplement guides either do not know about or choose to ignore.

The subgroup analysis told a different story. When the authors stratified by dose, studies using more than 30 g/day showed a statistically significant reduction in permeability markers. Studies using lower doses did not reach significance. Duration mattered as well: short protocols of less than 2 weeks at high doses produced the clearest signal.

This creates a practical problem. The doses that showed statistical significance in the meta-analysis (above 30 g/day) are substantially higher than what most people take, and higher than the 15 g/day dose that worked in the Zhou trial. The discrepancy likely reflects different study populations: Zhou enrolled patients with confirmed barrier dysfunction, while the meta-analysis pooled across heterogeneous populations including healthy athletes and surgical patients.

Supporting Studies

A 2021 trial published in Frontiers in Nutrition examined glutamine combined with a low-FODMAP diet in IBS patients. The combination group showed greater symptom improvement than either intervention alone, suggesting glutamine may enhance the efficacy of dietary interventions rather than competing with them. This aligns with how functional medicine practitioners use glutamine: as part of a protocol, not as a standalone fix.

Critically ill patients provide additional data points. A systematic review (PMC 6709840) of enteral glutamine supplementation in ICU settings found improvements in intestinal permeability markers and reduced infectious complications. The doses used in critical care (20 to 30 g/day) overlap with the meta-analysis threshold for significance, reinforcing the dose-response relationship.

A 2025 review in SAGE Open Medicine surveyed the full landscape of glutamine's therapeutic potential, confirming its role in mucosal repair, immune modulation, and barrier maintenance while noting the gap between mechanistic certainty and clinical trial volume.

Evidence Grade: B

L-glutamine earns a Grade B for intestinal permeability. One strong RCT with a large effect size, a meta-analysis with a positive subgroup finding at higher doses, and robust mechanistic evidence supporting the biological plausibility of the intervention. The evidence does not reach Grade A because the meta-analysis overall result was null, and we lack multiple large RCTs confirming the Zhou findings across different patient populations.

For context on our grading system, see our best supplements for autoimmune disease guide.

The Right Dose (Why 5 g/Day May Not Be Enough)

Most supplement labels recommend 5 g/day. Most online guides echo this number. The clinical evidence points to a different conclusion.

Standard dose (5 to 10 g/day): Adequate for general maintenance and mild support. No RCT has demonstrated significant permeability improvement at this dose. This is the dose range found in most commercial gut health products, and it may be sufficient for individuals without documented barrier dysfunction.

Clinical trial dose (15 g/day): The dose that produced the 79.6% response rate in the Zhou RCT. Split into three doses of 5 g, taken on an empty stomach. This is the first evidence-based threshold to consider if you have documented or suspected intestinal permeability issues.

Meta-analysis threshold (above 30 g/day): The dose range that reached statistical significance for permeability reduction across pooled studies. Typically used for short loading phases of 1 to 2 weeks rather than long-term maintenance.

Practical protocol: A phased approach accounts for both the meta-analysis finding and the Zhou trial data. Start with a 2-week loading phase at 20 to 30 g/day (three divided doses on an empty stomach), then step down to the therapeutic range of 10 to 15 g/day for 6 weeks, then maintain at 5 g/day long-term. Powder is the only practical format at therapeutic doses. Capsules typically contain 500 mg to 1 g each, meaning you would need 15 to 30 capsules per day during the loading phase.

Body weight consideration: Some practitioners calculate glutamine dosing by body weight, typically 0.3 to 0.5 g per kilogram per day for therapeutic purposes. A 70 kg (154 lb) person would land at 21 to 35 g/day, aligning closely with the meta-analysis threshold. This approach individualizes the loading phase dose rather than applying a flat number to everyone.

Cost at therapeutic doses: Pure L-glutamine powder costs roughly $0.03 to $0.06 per gram at retail prices. A loading phase at 30 g/day runs about $1 to $2 per day. Maintenance at 5 g/day costs under $0.30 per day. Among gut-healing interventions, glutamine offers the best cost-to-evidence ratio available.

Discuss all dosing with your healthcare provider before starting, particularly the loading phase.

Does Leaky Gut Cause Weight Gain?

The relationship between intestinal permeability and body weight runs through a specific inflammatory mechanism: lipopolysaccharide (LPS) translocation.

LPS is a component of gram-negative bacterial cell walls. In a healthy gut, LPS stays in the intestinal lumen where it belongs. When tight junctions fail and permeability increases, LPS crosses into the bloodstream. This is called metabolic endotoxemia, and it has been documented in obese individuals at levels 20% higher than in lean controls.

Circulating LPS binds to toll-like receptor 4 (TLR4) on immune cells and adipocytes, triggering a chronic low-grade inflammatory response. This inflammation drives insulin resistance through direct interference with insulin receptor signaling. Insulin resistance promotes fat storage, particularly visceral fat. The cycle reinforces itself: visceral fat produces its own inflammatory cytokines, further degrading barrier function.

Zonulin levels correlate with BMI and insulin resistance in multiple observational studies (PMC 10112051). Higher zonulin means more permeable gut, more LPS translocation, and stronger association with metabolic dysfunction.

Cani et al. (2007) provided some of the foundational animal data. Mice fed a high-fat diet developed metabolic endotoxemia, with plasma LPS levels increasing two to three-fold. The inflammatory cascade that followed produced insulin resistance, weight gain, and hepatic steatosis. When the researchers administered antibiotics to reduce gut bacterial load (and therefore LPS production), the metabolic consequences improved despite the unchanged diet. This suggests the permeability pathway has a causal role in animal models.

The caveat is important: this is association, not proven causation in humans. No RCT has demonstrated that healing intestinal permeability directly causes weight loss. The mechanistic pathway is plausible and well-documented in animal models. Human data remains correlational. Fixing a leaky gut will not replace caloric deficit for weight loss. It may, however, reduce the systemic inflammation that makes metabolic health harder to achieve.

One practical observation: many patients report reduced bloating, water retention, and abdominal distension when they address intestinal permeability. These changes can register on the scale without reflecting true fat loss. Reduced inflammation also improves insulin sensitivity, which can make dietary changes more effective. The weight connection is real but indirect.

L-Glutamine for Autoimmune Conditions

Fasano's model of autoimmune disease development requires three ingredients: genetic susceptibility, an environmental trigger, and increased intestinal permeability. Remove any one factor and the disease process stalls. This is why gut healing occupies Tier 1 in autoimmune protocols: it addresses the one factor most amenable to intervention.

Hashimoto's Thyroiditis

The gut-thyroid axis is well-documented. Hashimoto's patients show higher rates of intestinal permeability, SIBO, and celiac disease compared to the general population. Up to 10% of Hashimoto's patients have concurrent celiac disease, and a larger percentage show elevated zonulin levels without meeting celiac diagnostic criteria. The AIP diet for Hashimoto's addresses the dietary trigger side. L-glutamine addresses the barrier repair side.

Standard Hashimoto's protocols include L-glutamine as part of the 4R gut healing framework (Remove, Replace, Reinoculate, Repair), where glutamine falls under the Repair phase. The Remove phase eliminates inflammatory triggers (gluten, processed foods, individual sensitivities). Replace addresses digestive insufficiency (stomach acid, enzymes). Reinoculate restores beneficial bacteria. Repair provides the building blocks for mucosal regeneration, with glutamine as the centerpiece alongside zinc carnosine and collagen peptides.

For the complete Hashimoto's supplement stack and how glutamine fits alongside selenium, vitamin D, and other interventions, see our supplements for Hashimoto's guide. The Hashimoto's natural treatment pillar page covers the full protocol framework.

Crohn's Disease and Ulcerative Colitis

Active IBD depletes plasma glutamine levels significantly. The inflamed intestinal mucosa consumes glutamine at accelerated rates while systemic catabolism (muscle wasting, inflammatory cytokine production) simultaneously increases demand. This creates a functional deficit at precisely the time the gut needs glutamine most.

Crohn's patients present a particular challenge. The disease often affects the terminal ileum, the primary site of glutamine absorption. Inflammation in this region can impair the very uptake mechanism needed for therapeutic effect, which may explain why some IBD glutamine trials have shown inconsistent results. Higher doses and longer treatment periods may be necessary to overcome this absorption barrier.

The PRODUCE trial (2022, JAMA) demonstrated that dietary approaches (SCD and Mediterranean diets) can induce remission in mild-to-moderate IBD. L-glutamine supplementation during dietary intervention provides the raw material for mucosal repair alongside the anti-inflammatory dietary shift. For patients considering advanced interventions like low dose naltrexone for autoimmune disease, glutamine serves as a foundational complement at a fraction of the cost and complexity.

Celiac Disease

Celiac disease is the clearest example of the Fasano triad in action: HLA-DQ2/DQ8 genetic susceptibility, gliadin as the environmental trigger, and zonulin-mediated permeability as the gateway. L-glutamine supports intestinal barrier repair during the healing phase after gluten-free diet (GFD) initiation. It does not replace GFD. No supplement replaces strict gluten elimination in celiac disease.

Intestinal healing after GFD initiation takes 6 to 24 months in adults, and glutamine supplementation during this window provides metabolic support for the massive enterocyte turnover required to rebuild the villous architecture. Celiac patients must regenerate millions of villi that were flattened by the immune response. Each villus requires rapid epithelial cell proliferation, and those proliferating cells consume glutamine as their primary fuel. This is a supportive role, not a primary treatment.

For more on how autoimmune disease symptoms overlap across conditions and why gut healing applies broadly, see our condition-by-condition guide.

L-Glutamine vs BPC-157: Complement, Not Compete

Both compounds target gut healing, but they occupy entirely different positions in terms of evidence, cost, and accessibility.

L-Glutamine: Human RCT evidence (Grade B). Legal dietary supplement. Available in any health food store. Costs $15 to $30 per month at therapeutic doses. Mechanism centers on enterocyte fuel and tight junction support.

BPC-157: Animal evidence only (Grade C). No human RCTs published. Research compound, not FDA-approved for any indication. WADA banned since 2022. Costs $60 to $120 per month. Mechanism centers on angiogenesis, VEGF upregulation, and NO system modulation. Our BPC-157 gut healing guide covers the animal data and practical considerations in detail.

The rational sequencing: start with L-glutamine as a Tier 1 intervention (alongside AIP diet and other foundation supplements). If barrier dysfunction persists after 8 to 12 weeks of consistent glutamine use at therapeutic doses, BPC-157 enters the conversation as a Tier 3 option. The two compounds target different mechanisms and can be used together, but the evidence hierarchy argues for starting with the intervention that has human trial data.

Zinc carnosine deserves mention here as a Tier 1 complement to glutamine. While glutamine fuels enterocytes and supports tight junctions, zinc carnosine coats the mucosal surface and induces heat shock protein expression, providing a different layer of barrier protection. The combination of glutamine plus zinc carnosine covers two distinct protective mechanisms at a combined cost under $40 per month.

How to Take L-Glutamine

Form: Powder dissolved in water. Unflavored L-glutamine powder dissolves easily and has a mild, slightly sweet taste. Capsules become impractical above 5 g/day.

Timing: Empty stomach, 30 minutes before meals. Glutamine competes with other amino acids for absorption. Taking it away from protein-containing meals improves uptake.

Stability: L-glutamine is stable in dry powder form. It degrades in liquid over time, so mix immediately before drinking rather than preparing in advance. Heat accelerates degradation; do not add to hot beverages.

Stacking: Compatible with zinc carnosine (another Tier 1 gut compound), probiotics, and digestive enzymes. These are the four components of a standard gut repair protocol.

Duration: The Zhou trial ran for 8 weeks. The meta-analysis found the strongest effects with short-duration, high-dose protocols. A reasonable minimum commitment is 8 to 12 weeks at therapeutic doses before evaluating response.

What to expect: Some patients notice reduced bloating and improved stool consistency within the first 1 to 2 weeks, particularly during the loading phase. Others take 4 to 6 weeks to observe changes. Glutamine does not produce dramatic, overnight results. Barrier repair is a biological process that requires sustained substrate availability. If you notice no improvement after 12 weeks at therapeutic doses, reassess with your provider. Persistent symptoms despite adequate glutamine may indicate an unaddressed upstream issue: ongoing dietary triggers, SIBO, or another source of barrier disruption that requires targeted intervention.

Safety and Who Should Avoid L-Glutamine

L-glutamine has an excellent safety profile for most people. It is a conditionally essential amino acid found abundantly in dietary protein (meat, fish, eggs, dairy, beans). Supplemental doses of 15 to 30 g/day have been used in clinical trials and critical care settings without significant adverse events.

Hepatic encephalopathy and severe liver disease: Glutamine is metabolized to glutamate and ammonia. Patients with impaired hepatic ammonia clearance risk worsening encephalopathy. This is an absolute contraindication.

Active cancer: Glutamine fuels rapidly dividing cells. While the body's own glutamine supply already feeds tumor cells regardless of supplementation, oncologists generally recommend avoiding supplemental glutamine during active cancer treatment. Discuss with your oncologist.

Renal impairment: High-dose glutamine increases nitrogen load. Severe kidney disease may impair clearance. Use lower doses with medical supervision.

Drug interactions: Minimal. Glutamine does not have clinically significant interactions with common medications. However, if you take anticonvulsants (which work partly by modifying glutamate signaling), discuss supplementation with your neurologist.

Pregnancy and breastfeeding: Insufficient safety data at supplemental doses above dietary norms. Standard dietary intake through food is considered safe. Therapeutic doses (above 10 g/day) have not been studied in pregnant or breastfeeding women. Consult your OB-GYN before supplementing.

Side effects at high doses: Some individuals report mild gastrointestinal discomfort, nausea, or changes in bowel habits during the loading phase (20 to 30 g/day). These effects typically resolve within 2 to 3 days. If persistent, reduce to the therapeutic dose (10 to 15 g/day) and extend the protocol duration to compensate. Starting with 10 g/day and titrating upward over a week is a practical alternative for sensitive individuals.

Frequently Asked Questions

How long does L-glutamine take to heal leaky gut?

The Zhou 2019 RCT showed significant improvements within 8 weeks at 15 g/day. The 2024 meta-analysis found the strongest permeability effects with short, high-dose protocols of 1 to 2 weeks. A reasonable expectation: initial symptom improvement (reduced bloating, more formed stools, less post-meal discomfort) within 2 to 4 weeks at therapeutic doses, with continued barrier repair over 8 to 12 weeks. Full mucosal healing in conditions like celiac disease takes 6 to 24 months regardless of supplementation. The timeline depends heavily on the underlying cause of permeability. Post-infectious gut damage (as in the Zhou trial) may heal faster than chronic autoimmune-driven barrier dysfunction.

Can I take L-glutamine with other gut healing supplements?

Yes. L-glutamine stacks well with zinc carnosine, probiotics, and digestive enzymes. This combination forms the standard 4R gut repair protocol used in functional medicine. BPC-157 targets different mechanisms (angiogenesis versus enterocyte fuel) and can be added as a Tier 3 option if needed. Space glutamine 30 minutes before meals; probiotics can be taken with or without food depending on the strain.

Is L-glutamine safe to take long-term?

For most people, yes. Glutamine is a naturally occurring amino acid consumed in significant quantities through normal dietary protein intake (5 to 10 g/day from food alone). Long-term maintenance doses of 5 g/day are well within physiological ranges. Higher therapeutic doses (15 to 30 g/day) are typically used for defined periods of 8 to 12 weeks rather than indefinitely, though clinical trials have not identified safety concerns with extended use at these levels.

Does L-glutamine help with food sensitivities?

Possibly, through an indirect mechanism. Food sensitivities often correlate with increased intestinal permeability. When tight junctions fail, larger-than-normal food protein fragments cross into the lamina propria and encounter immune cells that would never see them in a healthy gut. These encounters trigger IgG and IgA-mediated responses that manifest as delayed food reactions: bloating, joint pain, skin eruptions, fatigue hours after eating. By supporting tight junction integrity and barrier repair, glutamine may reduce the antigen load that drives these reactions. This is a mechanistic inference, not a finding from a food sensitivity-specific RCT. Dietary elimination (such as the AIP protocol) addresses food sensitivities more directly, and the two approaches work well together: eliminate triggers while simultaneously repairing the barrier that allowed the sensitization in the first place.

Should I take L-glutamine powder or capsules?

Powder. At therapeutic doses of 10 to 15 g/day, you would need 10 to 30 capsules daily (most capsules contain 500 mg to 1,000 mg). Powder dissolves in water, costs less per gram, and allows precise dose titration. Capsules are practical only at maintenance doses of 5 g/day or below. Look for unflavored, pure L-glutamine powder without additives. A 500 g container typically costs $20 to $35 and lasts roughly one month at therapeutic doses. Pharmaceutical-grade (USP-verified) is preferable, though the amino acid itself is straightforward to manufacture and purity is generally high across reputable brands.

What is the difference between L-glutamine and glutamine?

L-glutamine is the biologically active form of the amino acid glutamine. The "L" refers to its left-handed molecular orientation, which is the form your body produces and uses. Supplement labels may say "L-glutamine" or simply "glutamine" interchangeably. Both refer to the same compound. D-glutamine (the right-handed form) is not biologically active and is not sold as a supplement. When you see "glutamine" on a supplement label, you are getting L-glutamine.

Next Steps

If you have an autoimmune condition and suspect gut barrier dysfunction, L-glutamine belongs in your Tier 1 protocol alongside vitamin D, omega-3, and dietary modification. The evidence supports doses well above what most supplement labels recommend.

Your optimal protocol depends on your specific condition, severity, current medications, and lab markers. Our free quiz builds a personalized protocol based on your answers, grading each intervention by evidence strength and sequencing them into a practical timeline.

This article is for educational purposes only. It does not constitute medical advice and should not replace consultation with your physician. Discuss all supplement protocols, including L-glutamine dosing, with your healthcare provider before starting.